ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

Integration of targeted therapies and immunotherapies offers new hope, enhancing survival rates and quality of life. Patients with mantle cell lymphoma experienced better survival rates when treated ...

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades. Treatment — ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

With three BTK inhibitors approved for treatment of mantle cell lymphoma, patients and providers should consider side effects and insurance coverage before deciding on a drug. Bruton tyrosine kinase ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and aggressive ...

Mantle cell lymphoma (MCL) is rare and difficult to manage, since it can range from a slow-growing disease to an aggressive form that is difficult to control. Fortunately, a new wave of treatments and ...

Mantle cell lymphoma is a cancer that often goes through phases of remission and relapse. During remission, doctors will continue to monitor a person for signs of relapse. They may also use certain ...